Last reviewed · How we verify
Peripheral vascular disease — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Brilinta | ticagrelor | AstraZeneca | P2Y12 Platelet Inhibitor [EPC] | Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12 | ||
| Brilinta | Brilinta | AstraZeneca | Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Peripheral vascular disease
- AstraZeneca · 2 drugs in Peripheral vascular disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Peripheral vascular disease:
- Peripheral vascular disease treatment updates — RSS
- Peripheral vascular disease treatment updates — Atom
- Peripheral vascular disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Peripheral vascular disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peripheral-vascular-disease. Accessed 2026-06-10.
Related
- Peripheral vascular disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing